Proteomic profiling of neurodegenerative diseases.

Aziz Maqbool*

Department of Clinical & Diagnostic Sciences, The University of Alabama at Birmingham, USA

Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), pose significant challenges to healthcare due to their complex pathophysiology and the lack of effective treatments. Proteomic profiling, the large-scale study of proteins, has emerged as a powerful approach to unravel the molecular mechanisms underlying these diseases, identify potential biomarkers for early diagnosis, and discover novel therapeutic targets [1, 2].

Proteomics is the comprehensive analysis of the entire protein complement of a cell, tissue, or organism. Unlike genomics, which provides static information about the potential of an organism, proteomics offers dynamic insights into the actual functional molecules that drive biological processes. Modern proteomic technologies, such as mass spectrometry (MS) and two-dimensional gel electrophoresis (2-DE), allow for the identification, quantification, and characterization of thousands of proteins simultaneously. Early and accurate diagnosis of neurodegenerative diseases is critical for effective intervention and management. Proteomic profiling has led to the identification of potential biomarkers in cerebrospinal fluid (CSF), blood, and brain tissues. For example, in Alzheimer's disease, altered levels of amyloid-beta (Aβ) peptides and tau proteins in CSF are considered hallmark biomarkers. Similarly, in Parkinson's disease, alpha-synuclein and DJ-1 proteins have been implicated as potential biomarkers [3].

Neurodegenerative diseases are characterized by the accumulation of misfolded proteins, oxidative stress, mitochondrial dysfunction, and neuroinflammation. Proteomic studies have provided insights into these pathogenic processes. In Alzheimer's disease, proteomic analysis has revealed dysregulation of synaptic proteins and pathways involved in energy metabolism and oxidative stress. In Parkinson's disease, proteomics has highlighted alterations in proteins related to mitochondrial function and protein degradation pathways. Identifying proteins that are differentially expressed in neurodegenerative diseases can uncover novel therapeutic targets. Proteomic profiling has identified several such targets, including kinases, phosphatases, and chaperone proteins. For instance, in Huntington's disease, proteomic studies have pointed to the role of heat shock proteins (HSPs) in modulating the aggregation of mutant huntingtin protein, suggesting that enhancing HSP function could be a therapeutic strategy. MS is a cornerstone of proteomic analysis. It allows for the precise identification and quantification of proteins by measuring the mass-to-charge ratio of ionized protein fragments. Advances in MS, such as tandem MS (MS/MS) and label-free quantification, have significantly increased the sensitivity and throughput of proteomic studies [4, 5].

2-DE separates proteins based on their isoelectric point and molecular weight, enabling the resolution of complex protein mixtures. Combined with MS, 2-DE is a powerful technique for identifying protein isoforms and post-translational modifications (PTMs) that are often associated with neurodegenerative diseases. The vast amount of data generated by proteomic studies necessitates robust bioinformatics tools for data analysis and interpretation. Tools such as MaxQuant, Proteome Discoverer, and Skyline facilitate protein identification, quantification, and PTM analysis. Additionally, pathway analysis tools like Ingenuity Pathway Analysis (IPA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) help in understanding the biological significance of proteomic findings [6, 7].

Despite significant advancements, proteomic profiling of neurodegenerative diseases faces several challenges. The complexity and heterogeneity of these diseases, coupled with the dynamic nature of the proteome, require advanced technologies and analytical methods. Moreover, translating proteomic findings into clinical practice remains a formidable task. Future research should focus on integrating proteomics with other omics approaches, such as genomics, transcriptomics, and metabolomics, to obtain a holistic understanding of neurodegenerative diseases. Additionally, the development of more sensitive and specific proteomic techniques will enhance biomarker discovery and the identification of therapeutic targets [8, 9].

Proteomic profiling has revolutionized the study of neurodegenerative diseases by providing unprecedented insights into their molecular underpinnings. Through the identification of biomarkers, elucidation of disease mechanisms, and discovery of therapeutic targets, proteomics holds great promise for improving the diagnosis, treatment, and management of neurodegenerative diseases. As technologies advance and our understanding deepens, proteomics will continue to play a crucial role in combating these debilitating disorders [10].

References

1. Raghunathan R, Turajane K, Wong LC. Biomarkers in neurodegenerative diseases: proteomics spotlight on ALS and Parkinson’s disease. Int J Mol Sci. 2022;23(16):9299.

***Correspondence to:** Aziz Maqbool, Department of Clinical & Diagnostic Sciences, The University of Alabama at Birmingham, USA. E-mail: amaqbool@uab.edu

***Received:** 25-Jul-2024, Manuscript No. AAAIB-24-144207; **Editor assigned:** 27-Jul-2024, PreQC No. AAAIB-24-144207 (PQ); **Reviewed:** 08-Aug-2024, QC No. AAAIB-24-144207; **Revised:** 20-Aug-2024, Manuscript No. AAAIB-24-144207 (R); **Published:** 26-Aug-2024, DOI: 10.35841/aaaib- 8.4.223*

***Citation:** Maqbool A. Proteomic profiling of neurodegenerative diseases. Arch Ind Biot. 2024; 8(4):223*

2. Brandebura AN, Paumier A, Onur TS, et al. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat Rev Neurosci. 2023;24(1):23-39.
3. Ge YJ, Ou YN, Deng YT, et al. Prioritization of drug targets for neurodegenerative diseases by integrating genetic and proteomic data from brain and blood. Biol Psychiatry. 2023;93(9):770-9.
4. Bhatia HS, Brunner AD, Öztürk F, et al. Spatial proteomics in three-dimensional intact specimens. Cell. 2022;185(26):5040-58.
5. Yang C, Farias FH, Ibanez L, et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci. 2021;24(9):1302-12.
6. Rayaprolu S, Bitarafan S, Santiago JV, et al. Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain. Nat Commun. 2022;13(1):2927.
7. Karayel O, Winter SV, Padmanabhan S, et al. Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson's disease. Cell Rep Med. 2022;3(6).
8. Oh HS, Rutledge J, Nachun D, et al. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023;624(7990):164-72.
9. Bai B, Vanderwall D, Li Y, et al. Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. Mol Neurodegener. 2021;16(1):55.
10. König T, Nolte H, Aaltonen MJ, et al. MIROs and DRP1 drive mitochondrial-derived vesicle biogenesis and promote quality control. Nat Cell Biol. 2021;23(12):1271-86.

Citation: *Maqbool A. Proteomic profiling of neurodegenerative diseases. Arch Ind Biot. 2024; 8(4):223*